COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Jun 25, 2007	25-NSE	25-NSE	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001354457-07-000187.pdf 0001354457-07-000187.rtf
Jun 22, 2007	25-NSE	25-NSE	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001296945-07-000009.pdf 0001296945-07-000009.rtf
Jun 16, 2004	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-04-103997.pdf 0001193125-04-103997.rtf 0001193125-04-103997.xls
Jun 09, 2006	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-06-127453.pdf 0001193125-06-127453.rtf 0001193125-06-127453.xls
Jun 06, 2008	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-08-129739.pdf 0001193125-08-129739.rtf 0001193125-08-129739.xls
Sep 06, 2001	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0000950144-01-506642.pdf 0000950144-01-506642.rtf 0000950144-01-506642.xls
Jun 05, 2009	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-09-126288.pdf 0001193125-09-126288.rtf 0001193125-09-126288.xls
Jun 13, 2007	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-07-134982.pdf 0001193125-07-134982.rtf 0001193125-07-134982.xls
Jun 01, 2011	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-11-156354.pdf 0001193125-11-156354.rtf 0001193125-11-156354.xls
Jun 17, 2003	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001096906-03-000353.pdf 0001096906-03-000353.rtf 0001096906-03-000353.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting January 15, 2021

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty ...

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference November 20, 2020

RALEIGH, N.C. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey , Chief Executive Officer, and ...

BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18 November 11, 2020

RALEIGH, N.C. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now